Additional Doses for Immunocompromised Patients
Additional Doses for immunocompromised patients who received Pfizer, Moderna, or Johnson & Johnson: Additional doses of the Pfizer and Moderna (mRNA) COVID-19 vaccines have been authorized for patients who are at least 28 days from their final dose of a Pfizer, Moderna, or Johnson & Johnson primary series and who are moderately or severely immunocompromised.
Immunocompromised patients 6 months through 4 years who received the Pfizer vaccine are recommended to receive a 3-dose primary series (2 monovalent doses and 1 bivalent dose).
Immunocompromised patients 6 months and older who completed a Moderna primary series, and immunocompromised patients 5 years and older who completed a Pfizer primary series may receive an additional (third) dose of an age-appropriate monovalent Pfizer or Moderna vaccine at least 28 days after their second dose. The additional dose should match the original vaccine series (for example, if you completed the Pfizer primary vaccine series, you will receive an additional dose of Pfizer). To ensure that you receive the correct vaccine, please bring a copy of your COVID-19 vaccine record to your appointment.
Immunocompromised patients ages 18 years and older who received the single-dose Johnson & Johnson vaccine may receive an additional dose of the monovalent Pfizer or Moderna vaccine at least 28 days later.
Patients who receive an additional dose should wait at least 2 months before receiving a bivalent booster.
At this time, additional doses have not been authorized for people who received the Novavax vaccine. If you are not sure whether you qualify for an additional dose of the Moderna or Pfizer vaccines, please consult with your physician.
Those who are moderately or severely immunocompromised (as defined by the CDC) qualify for an additional dose. Criteria include:
- Receiving active cancer treatment for tumors or cancers of the blood
- Received an organ transplant and are taking medicine to suppress the immune system
- Received chimeric antigen receptor (CAR)-T-cell therapy (a treatment to help your immune system attach to and kill cancer cells) or received a stem cell transplant within the last 2 years
- Moderate or severe primary immunodeficiency (e.g., DiGeorge, Wiskott-Aldrich syndromes)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory
For more information, see the CDC's COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised webpage.
Book an Appointment Find a drop-in clinic